Cetuximab and the Head and Neck Squamous Cell Cancer

Author(s): Riccardo Concu*, M. Natalia D.S. Cordeiro*

Journal Name: Current Topics in Medicinal Chemistry

Volume 18 , Issue 3 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The Head and Neck Squamous Cell Cancer (HNSCC) is the most common type of head and neck cancer (more than 90%), and all over the world more than a half million people have been developing this cancer in the last years. This type of cancer is usually marked by a poor prognosis with a really significant morbidity and mortality. Cetuximab received early favor as an exciting and promising new therapy with relatively mild side effect, and due to this, received authorization in 2004 from the European Medicines Agency (EMA) and in 2006 from the Food and Drug Association (FDA) for the treatment of patients with squamous cell cancer of the head and neck in combination with radiation therapy for locally advanced disease. In this work we will review the application and the efficacy of the Cetuximab in the treatment of the HNSCC.

Keywords: Cell, Cancer, Cetuximab, Food and Drug Association, Cytotoxic T lymphocytes, Epidermal growth factors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [192 - 198]
Pages: 7
DOI: 10.2174/1568026618666180112162412
Price: $65

Article Metrics

PDF: 56
HTML: 20